Patent · US Active

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

US11851680B2 · kind B2 · utility

0Cited by
6References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 17, 2022
Grant dateDec 26, 2023
Priority date
Expiry dateAug 17, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2330/51
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.